Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pazopanib in VEGF-TKI Refractory Metastatic Renal Cell Carcinoma (MRCC)

NCT01157091 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01157091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01157091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pazopanib in VEGF-TKI Refractory Metastatic Renal Cell Carcinoma (MRCC)
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2010
Completion date
December 31, 2013
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, recurrent renal cell cancer, stage iv renal cell cancer